Trials / Completed
CompletedNCT01591330
A Study of LY2140023 in Healthy Males and Females
A Particle Size Study of 3 Different Particle Size Test Tablet Formulations Compared to the Reference Tablet Formulation in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Denovo Biopharma LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the effect of different particle size of LY2140023. The study involves 4 single doses of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth with a washout period of at least 3 days between doses. This study will last approximately 60 days not including screening. Screening is required within 30 days prior to study entry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2140023 Reference form | 80-mg tablet administered orally |
| DRUG | LY2140023 Test-Low | 80-mg tablet administered orally |
| DRUG | LY2140023 Test-Medium | 80-mg tablet administered orally |
| DRUG | LY2140023 Test-High | 80-mg tablet administered orally |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-06-01
- Completion
- 2012-08-01
- First posted
- 2012-05-04
- Last updated
- 2021-09-21
- Results posted
- 2021-09-21
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01591330. Inclusion in this directory is not an endorsement.